Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07457944) titled 'Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients' on March 3.

Study Type: Observational

Primary Sponsor: Ruijin Hospital

Condition: Pemphigus Disease Rituximab (RTx)

Recruitment Status: Not recruiting

Date of First Enrollment: January 1, 2019

Target Sample Size: 275

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07457944

Published by HT Digital Content Services with permission from Health Daily Digest....